65 results on '"Pasinelli, Piera"'
Search Results
2. Characterizing Patient Preferences, Satisfaction, and Quality of Care Across Health Care Models in Amyotrophic Lateral Sclerosis (ALS) (P6-11.011)
3. Apoptotic cell death pathways in amyotrophic lateral sclerosis: a review
4. Amyotrophic Lateral Sclerosis
5. EphrinB2 knockdown in cervical spinal cord preserves diaphragm innervation in a mutant SOD1 mouse model of ALS
6. Editorial: The role of glial cells in neurodegeneration
7. Author Response: EphrinB2 knockdown in cervical spinal cord preserves diaphragm innervation in a mutant SOD1 mouse model of ALS
8. EphrinB2 knockdown in cervical spinal cord preserves diaphragm innervation in a mutant SOD1 mouse model of ALS
9. EphrinB2 knockdown in cervical spinal cord preserves diaphragm innervation in a mutant SOD1 mouse model of ALS
10. EphrinB2 knockdown in cervical spinal cord preserves diaphragm innervation in a mutant SOD1 mouse model of ALS
11. Glucose Hypometabolism Prompts RAN Translation and Exacerbates C9orf72-related ALS/FTD Phenotypes
12. EphrinB2 knockdown in spinal cord astrocytes preserves diaphragm innervation in a mutant SOD1 mouse model of ALS
13. Targeting TNFα produced by astrocytes expressing amyotrophic lateral sclerosis‐linked mutant fused in sarcoma prevents neurodegeneration and motor dysfunction in mice
14. A mouse model with widespread expression of the C9orf72-linked glycine–arginine dipeptide displays non-lethal ALS/FTD-like phenotypes
15. A mouse model with widespread expression of the C9orf72-linked glycine-arginine dipeptide displays non-lethal ALS/FTD-like phenotypes
16. A Mouse Model with Widespread Expression of the C9orf72-Linked Glycine-Arginine Dipeptide Displays Non-Lethal ALS/FTD-Like Phenotypes
17. Astrocytic expression of ALS-causative mutant FUS leads to TNFα-dependent neurodegeneration in vivo
18. Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
19. Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
20. Cover
21. Synaptic dysfunction in amyotrophic lateral sclerosis/frontotemporal dementia: Therapeutic strategies and novel biomarkers
22. In Vivo and In Vitro Determination of Cell Death Markers in Neurons
23. Synaptic dysfunction induced by glycine‐alanine dipeptides in C9orf72‐ ALS / FTD is rescued by SV 2 replenishment
24. Muscleblind acts as a modifier of FUS toxicity by modulating stress granule dynamics and SMN localization
25. Rethinking Drug Treatment Approaches in ALS by Targeting ABC Efflux Transporters
26. AAV2‐BDNF promotes respiratory axon plasticity and recovery of diaphragm function following spinal cord injury
27. Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis
28. Repeat‐associated non‐ AUG translation in C9orf72‐ ALS / FTD is driven by neuronal excitation and stress
29. Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha
30. Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies
31. Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS
32. Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene
33. Cell-to-Cell Transmission of Dipeptide Repeat Proteins Linked to C9orf72 -ALS/FTD
34. Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P‐Glycoprotein) in endothelial cells of the blood–brain barrier in mutant superoxide dismutase 1‐linked amyotrophic lateral sclerosis
35. Pur-alpha regulates cytoplasmic stress granule dynamics and ameliorates FUS toxicity
36. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders
37. ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis
38. Antisense Proline-Arginine RAN Dipeptides Linked to C9ORF72-ALS/FTD Form Toxic Nuclear Aggregates that Initiate In Vitro and In Vivo Neuronal Death
39. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics
40. Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis
41. Defects in Synapse Structure and Function in a Fly Model of FUS-Related ALS
42. Defects in Synapse Structure and Function Precede Motor Neuron Degeneration inDrosophilaModels of FUS-Related ALS
43. Selective increase of two ABC drug efflux transporters at the blood–spinal cord barrier suggests induced pharmacoresistance in ALS
44. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1
45. Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2
46. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS
47. Voltage-dependent Inwardly Rectifying Potassium Conductance in the Outer Membrane of Neuronal Mitochondria
48. ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2
49. Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: Therapeutic implications for amyotrophic lateral sclerosis
50. A Caspase-3-cleaved Fragment of the Glial Glutamate Transporter EAAT2 Is Sumoylated and Targeted to Promyelocytic Leukemia Nuclear Bodies in Mutant SOD1-linked Amyotrophic Lateral Sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.